BioAdaptives, Inc. (BDPT) stock

BDPTOTCPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 3/30

$0.00−0.00 (-5.56%)

Close on Oct 19, 2026Market cap $478.03KP/E –Yield –

BioAdaptives r&d expenses

Research and development expenses are spending on new products and technology.

BioAdaptives has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in BioAdaptives's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jan 23, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BDPT.

Revenue growth694.1% · median -25.0%

Operating margin-3557.0% · median -7414.5%

Net margin-4553.2% · median -7737.8%

Advertisement
300 × 250

See a number that looks wrong?